Suppr超能文献

两种平滑组织扩张器(Artoura和CPX4)的安全性概况比较

Safety Profile Comparison of 2 Smooth Tissue Expander Types: Artoura and CPX4.

作者信息

Almeida Mariana N, Alper David P, Williams Mica C G, Shah Rema, Ihnat Jacqueline M H, Hu Kevin, Parikh Neil, Alperovich Michael

机构信息

From the Division of Plastic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT.

出版信息

Ann Plast Surg. 2024 Aug 1;93(2):178-182. doi: 10.1097/SAP.0000000000004019. Epub 2024 Jul 5.

Abstract

INTRODUCTION

With the recent transition to smooth tissue expanders (TEs), functional differences between TE subtypes have not been fully elucidated. This study evaluated the differences in TE characteristics and complications between 2 commonly used Mentor smooth TE models, Artoura and CPX4.

METHODS

A retrospective review of patients who received either smooth Mentor Artoura or CPX4 TE from 2012 to 2022 was conducted. Demographic data, perioperative information, pain scores, TE variables, cancer characteristics, and complications were collected. A multivariate analysis was used to evaluate the relationship between TE subtype and complications while controlling for demographic, TE characteristics, radiation, and chemotherapy exposure.

RESULTS

During the study period, 62 smooth Artoura TEs and 79 smooth CPX4 TEs were used. Patients who received CPX4 smooth implants tended to be older (51.09 vs 46.18 years old, P = 0.02) and have a higher body mass index (28.66 vs 23.50 kg/m 2 , P < 0.001). There were no differences among patient comorbidities. CPX4 required on average a greater total fill volume (422.23 vs 348.07 mL, P = 0.01) and had a greater drain duration (16.91 vs 14.33 days, P = 0.05). There were no differences in TE plane placement between Artoura and CPX4. Additionally, there were no differences in complication rates, including infection, hematomas, seromas, wound breakdown, TE replacement, and capsular contracture. When controlling for body mass index, diabetes, TE plane placement, acellular dermal matrix use, radiation exposure, and chemotherapy, there was no association between TE subtype and any individual complication.

DISCUSSION

Differences in total fill volume and drain duration were significantly different between Mentor Artoura and CPX4 implants, which may influence TE subtype selection. However, Artoura and CPX4 have excellent and equivalent safety profiles with similar complication rates, even when controlling for demographic and TE characteristics.

摘要

引言

随着近期向平滑组织扩张器(TEs)的转变,TE亚型之间的功能差异尚未完全阐明。本研究评估了两种常用的Mentor平滑TE模型Artoura和CPX4在TE特征和并发症方面的差异。

方法

对2012年至2022年期间接受平滑Mentor Artoura或CPX4 TE的患者进行回顾性研究。收集人口统计学数据、围手术期信息、疼痛评分、TE变量、癌症特征和并发症。在控制人口统计学、TE特征、放疗和化疗暴露的同时,采用多变量分析评估TE亚型与并发症之间的关系。

结果

在研究期间,使用了62个平滑Artoura TE和79个平滑CPX4 TE。接受CPX4平滑植入物的患者往往年龄较大(51.09岁对46.18岁,P = 0.02)且体重指数较高(28.66对23.50 kg/m²,P < 0.001)。患者合并症之间无差异。CPX4平均需要更大的总填充量(422.23对348.07 mL,P =

引言

随着近期向平滑组织扩张器(TEs)的转变,TE亚型之间的功能差异尚未完全阐明。本研究评估了两种常用的Mentor平滑TE模型Artoura和CPX4在TE特征和并发症方面的差异。

方法

对2012年至2022年期间接受平滑Mentor Artoura或CPX4 TE的患者进行回顾性研究。收集人口统计学数据、围手术期信息、疼痛评分、TE变量、癌症特征和并发症。在控制人口统计学、TE特征、放疗和化疗暴露的同时,采用多变量分析评估TE亚型与并发症之间的关系。

结果

在研究期间,使用了62个平滑Artoura TE和79个平滑CPX4 TE。接受CPX4平滑植入物的患者往往年龄较大(51.09岁对46.18岁,P = 0.02)且体重指数较高(28.66对23.50 kg/m²,P < 0.001)。患者合并症之间无差异。CPX4平均需要更大的总填充量(422.23对348.07 mL,P = 0.01)且引流持续时间更长(16.91对14.33天,P = 0.05)。Artoura和CPX4在TE平面放置上无差异。此外,并发症发生率,包括感染、血肿、血清肿、伤口裂开、TE置换和包膜挛缩,无差异。在控制体重指数、糖尿病、TE平面放置、无细胞真皮基质使用、放疗暴露和化疗后,TE亚型与任何个体并发症之间无关联。

讨论

Mentor Artoura和CPX4植入物在总填充量和引流持续时间上存在显著差异,这可能会影响TE亚型的选择。然而,即使在控制人口统计学和TE特征后,Artoura和CPX4仍具有出色且相当的安全性,并发症发生率相似。 0.01)且引流持续时间更长(16.91对14.33天,P = 0.05)。Artoura和CPX4在TE平面放置上无差异。此外,并发症发生率,包括感染、血肿、血清肿、伤口裂开、TE置换和包膜挛缩,无差异。在控制体重指数、糖尿病、TE平面放置、无细胞真皮基质使用、放疗暴露和化疗后,TE亚型与任何个体并发症之间无关联。

讨论

Mentor Artoura和CPX4植入物在总填充量和引流持续时间上存在显著差异,这可能会影响TE亚型的选择。然而,即使在控制人口统计学和TE特征后,Artoura和CPX4仍具有出色且相当的安全性,并发症发生率相似。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验